The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
A late-stage study of Sanofi and Regeneron’s Dupixent in adolescents with atopic dermatitis has met its key targets, paving the way for a regulatory submission for drug targeting this younger patient group in the third quarter.
The Cell and Gene Therapy Catapult (CGT Catapult) has announced a major investment in skills and capability training to help accelerate integration of cell and gene therapies into health services following their regulatory approval.
The Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the National Centre for the Replacement Refinement & Reduction of Animals in Research are working together to “propel” the UK into the race to advance organ on a chip technology.
The NHS Confederation has launched a petition urging the government to commit to a funding plan for health and social care to 2035, to help address “crippling effects” of rising demand, underfunding and workforce shortages.
Coeliac UK and the UK’s Innovation Agency, Innovate UK are now taking applications from businesses and researchers wishing to access a fund of £750,000 to improve the detection and management of coeliac disease.